Vertex Pharmaceuticals (VRTX) Cash & Current Investments (2009 - 2026)

Vertex Pharmaceuticals' Cash & Current Investments history runs 18 years deep, the most recent figure standing at $7.2 billion for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 16.86% year-over-year to $7.2 billion; the TTM figure through Mar 2026 stood at $7.2 billion (up 16.86% YoY), while the FY2025 annual figure was $6.6 billion, up 8.05% from the prior year.
• Cash & Current Investments was $7.2 billion for Q1 2026 at Vertex Pharmaceuticals, up from $6.6 billion in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $11.9 billion in Q3 2023 to a low of $5.8 billion in Q2 2024.
• Historically, Cash & Current Investments has averaged $8.5 billion across 5 years, with a median of $8.2 billion in 2022.
• The sharpest annual moves came in 2022 and 2024: Cash & Current Investments jumped 43.24% in 2022, then sank 48.42% in 2024.
• A 5-year view of Cash & Current Investments shows it stood at $10.8 billion in 2022, then gained by 4.08% to $11.2 billion in 2023, then sank by 45.48% to $6.1 billion in 2024, then gained by 8.05% to $6.6 billion in 2025, then climbed by 9.66% to $7.2 billion in 2026.
• The last three Cash & Current Investments figures came in at $7.2 billion (Q1 2026), $6.6 billion (Q4 2025), and $6.3 billion (Q3 2025), per Business Quant data.